Henri von Haarman (Nanoform Finland Oyj)

von Haartman, Henri (Nanoform 201907– Director Investor Relations)

	Organisation	Nanoform Finland Oyj
	Group	Nanoform (Group)
	Product	public relations / investor relations / marcom (services)
	Product 2	nanonization™ technology

Nanoform Finland Oyj. (7/10/19). "Press Release: Nanoform Appoints Director of Investor Relations Following International Growth". Helsinki.

Nanoform, an innovative medicine enabling nanotechnology company, has appointed Henri von Haartman as Director of Investor Relations. The newly created role will enrich investor relations as Nanoform seeks to further its shareholder base and continue its international growth, including expansion into the US market.

Henri von Haartman has over 20 years’ experience as an equity capital markets and investment banking manager for global and local tier 1 investment banks. This includes experience in senior positions at Deutsche Bank and Salomon Brothers, which later became Citigroup Global Markets. His most recent role involved successfully building the equity capital market for a Swedish investment banking company.

The appointment follows Nanoform’s rapid growth during the last year, with the employment of internationally renowned experts in senior positions facilitating expansion into international markets. The role of Director of Investor Relations will ensure that the value of Nanoform’s proprietary nanonizationTM technology is effectively communicated to global investors.

Albert Hæggström, CFO of Nanoform said: “I have known many professionals in the global finance industry over the years, but Henri truly stands out. His drive and expertise are evidenced by his exceptional track record. I am really pleased that he has joined the Nanoform team and look forward to working with him as our industry-changing technology is introduced to international investors.”

Henri von Haartman said: “Nanoform provides unparalleled nanonization technology, with the potential to become the gold standard in nanoparticle engineering and offer outstanding added value to the pharma industry. I’m truly honoured to accept this opportunity and sincerely look forward to working with the Nanoform team and leading institutional investors around the world.”

Notes to the Editor:

For further information, images and interview opportunities with Nanoform, please contact:

Lizzie Harrett at Notch Communications
lizzie.harrett@notchcommunications.co.uk
+44 (0) 161 457 7230

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization™ services. The company’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESS??) technology produces nanonized “designed-for-purpose” API particles, as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform’s unique nanonization™ technology provides novel opportunities in diverse value enhancing drug delivery applications.

For more information please visit http://www.nanoform.fi/